JAK2V617F突变加剧血栓炎症反应恶化脑静脉窦血栓形成的预后
研究通过小鼠脑静脉窦血栓形成(CVST)模型比较造血细胞限定表达Jak2V617F与野生型Jak2小鼠的临床、生物学及影像结局,并平行分析JAK2V617F阳性或阴性CVST患者队列。结果显示Jak2V617F小鼠血小板和中性粒细胞黏附增加、颅内出血更频繁严重且死亡率更高,患者中JAK2V617F阳性者血栓负荷倾向更高且全身免疫炎症指数显著更高。
要点
- Jak2V617F小鼠CVST后第1天颅内出血更频繁严重且死亡率更高
- Jak2V617F小鼠显示循环血小板-中性粒细胞聚集体升高、CD11b上调及髓过氧化物酶血浆水平升高
- JAK2V617F阳性CVST患者全身免疫炎症指数显著高于阴性患者,血栓负荷倾向更高
核心结论
- 在小鼠CVST模型中,Jak2V617F突变导致血栓负荷增加、颅内出血和死亡率升高的特定模式。
- 在小鼠和JAK2V617F阳性患者中均观察到的加剧血栓炎症反应可能促成出血并发症。
研究设计与样本
- 体内小鼠CVST模型,比较造血细胞限定表达Jak2V617F小鼠与野生型Jak2小鼠的临床、生物学及影像结局。
- 平行研究JAK2V617F阳性或阴性的CVST人类队列。
主要发现
- CVST早期,造血细胞表达Jak2V617F小鼠在CVST邻近脑静脉中血小板和中性粒细胞黏附增加。
- 第1天,Jak2V617F小鼠结局更差,颅内出血更频繁且更严重,死亡率更高。
- Jak2V617F小鼠外周中性粒细胞活化增强,表现为循环血小板-中性粒细胞聚集体升高、CD11b表达上调及髓过氧化物酶血浆水平升高。
- 免疫组织学和脑匀浆分析显示Jak2V617F小鼠中性粒细胞浸润更高及血脑屏障破坏增加。
- JAK2V617F阳性CVST患者血栓负荷倾向更高,全身免疫炎症指数显著高于JAK2V617F阴性患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cerebral venous sinus thrombosis (CVST) is an uncommon venous thromboembolic event accounting for <1% of strokes resulting in brain parenchymal injuries. JAK2V617F mutation, the most frequent driving mutation of myeloproliferative neoplasms, has been reported to be associated with worse clinical outcomes in patients with CVST. We investigated whether hematopoietic JAK2V617F expression predisposes to specific pathophysiological processes and/or worse prognosis after CVST. Using an in vivo mouse model of CVST, we analyzed clinical, biological, and imaging outcomes in mice with hematopoietic-restricted Jak2V617F expression, compared with wild-type Jak2 mice. In parallel, we studied a human cohort of JAK2V617F-positive or -negative CVST. Early after CVST, mice with hematopoietic Jak2V617F expression had increased adhesion of platelets and neutrophils in cerebral veins located in the vicinity of CVST. On day 1, Jak2V617F mice had a worse outcome characterized by significantly more frequent and severe intracranial hemorrhages (ICHs) and higher mortality rates. Peripheral neutrophil activation was enhanced, as indicated by higher circulating platelet-neutrophil aggregates, upregulated CD11b expression, and higher myeloperoxydase plasma level. Concurrently, immunohistological and brain homogenate analysis showed higher neutrophil infiltration and increased blood-brain barrier disruption. Similarly, patients with JAK2V617F-positive CVST tended to present higher thrombotic burden and had significantly higher systemic immune-inflammation index, a systemic thromboinflammatory marker, than patients who were JAK2V617F-negative. In mice with CVST, our study corroborates that Jak2V617F mutation leads to a specific pattern including increased thrombotic burden, ICH, and mortality. The exacerbated thromboinflammatory response, observed both in mice and patients positive for JAK2V617F, could contribute to hemorrhagic complications.
引用
- Bourrienne MC, Le Cam Duchez V, Faille D, et al. Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis. Blood Adv. 2024. PMID: 38386979. doi:10.1182/bloodadvances.2023011692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。